PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. The company offers various services, including transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. It also develops prepaid card solutions for corporate incentive and rewards, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, the company offers Co-Pay Assistance Program, a pharmaceutical payment card product; and Per Diem/Corporate Expense Payments that allows businesses, and nonÂprofits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, it provides Buy and Bill programs for patients to purchase directly from physician's office or through an infusion center for physician administered therapies; payment solution for source plasma collection centers; and PaySign Premier, a demand deposit account debit card, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and internationally. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. is based in Henderson, Nevada.
IPO Year:
Exchange: NASDAQ
Website: paysign.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $6.00 | Buy | Lake Street |
| 3/30/2022 | $4.00 | Mkt Perform | Barrington Research |
| 3/24/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 8/20/2021 | $3.50 | Neutral → Buy | DA Davidson |
| 8/19/2021 | Neutral → Buy | DA Davidson | |
| 8/12/2021 | $3.50 → $3.75 | Neutral → Buy | Ladenburg Thalmann |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
10-Q - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
10-Q - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
DEFA14A - Paysign, Inc. (0001496443) (Filer)
DEF 14A - Paysign, Inc. (0001496443) (Filer)
10-K - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
Live Leadership Updates
Paysign Strengthens Leadership in Technology for Plasma and Pharmaceutical Industries Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has acquired the assets of Gamma Innovation LLC (Gamma), significantly enhancing Paysign's capabilities in plasma donor and pharmaceutical patient engagement technologies. As part of this strategic acquisition, Paysign has appointed Michael Ngo, former Managing Member of Gamma, as its Chief Innovation Officer. "This acquisition represents an exciting milestone for Paysign as we accelerate our growth strategy and expand our
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Lake Street initiated coverage of PaySign with a rating of Buy and set a new price target of $6.00
Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00
Ladenburg Thalmann downgraded PaySign from Buy to Neutral
DA Davidson upgraded PaySign from Neutral to Buy and set a new price target of $3.50
DA Davidson upgraded PaySign from Neutral to Buy
Ladenburg Thalmann upgraded PaySign from Neutral to Buy and set a new price target of $3.75 from $3.50 previously
Ladenburg Thalmann upgraded PaySign from Sell to Neutral and set a new price target of $3.50
Fastest customizable press release news feed in the world
Company Positioned for Growth Serving Life Sciences Industries Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced that its board of directors has elected Dan Henry as Chairman of the Board, succeeding Mark Newcomer who will continue in his role as President and Chief Executive Officer. "Dan brings decades of experience in fintech, payments and leadership strategy along with a deep understanding of Paysign's business and long‑term goals," said Mark Newcomer, President and CEO of Paysign. "His vision and insi
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive pharma patient affordability offerings, financial technology products and integrated payment processing, today announced they will be presenting at the Oppenheimer 28th Annual Technology, Internet & Communications Conference to be held August 11-13, 2025, through a virtual format. The conference focuses on providing an expansive look across the dynamic sector of the world economy at existing and emerging technologies and providing potential investors the opportunity to evaluate public companies at the forefront of these technological innovations. Paysign's Chief Financial Officer, Jeff Baker, is sch
Second quarter 2025 total revenues of $19.08 million, up 33.1% from second quarter 2024 Second quarter 2025 net income of $1.39 million, up 99.1% from $697 thousand a year ago, while diluted earnings per share was $0.02, versus $0.01 for second quarter 2024 Second quarter 2025 Adjusted EBITDA of $4.51 million, up 101.8% from $2.24 million a year ago, while diluted Adjusted EBITDA per share was $0.08 versus $0.04 for second quarter 20241 Added 123 net plasma centers during second quarter 2025, all which went live June 16. We exited the quarter with 607 centers; average monthly revenue per plasma center decreased to $7,098 compared to $7,916 for the same period last year; year-over-
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, financial technology products and integrated payment processing, will discuss second quarter 2025 earnings at 5:00 p.m. Eastern time on Tuesday, August 5, 2025. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13754588 The replay will be available until November 5, 2025. To register as a financial professional in order to ask questions during the call, please email [email protected] no later than 5:00 p.m. Eastern time on Friday, Aug
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced the successful transition of 123 out of 132 newly awarded plasma donation centers. The remaining nine centers are on track to go live in the third quarter of 2025. The onboarding of 123 centers was completed in just one week – significantly ahead of schedule – demonstrating Paysign's operational agility, platform scalability and executional discipline. "Successfully transitioning this volume of centers in a single week is a testament to the strength of our platform, the rigor of our processes and the exceptional c
The Additions Significantly Increase the Company's U.S. Plasma Market Share Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has been awarded 132 established plasma donation centers through an expansion of its long-standing relationship with a major plasma collection company. Transition of the centers from the incumbent provider is underway, with 123 centers expected to be live by the end of the second quarter of 2025 and the remaining nine slated for transition during the third quarter of 2025. "The addition of these centers underscores the strengths of
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced its CFO, Jeff Baker, will be attending and presenting at the MicroCap Rodeo Spring Conference in New York City on Wednesday, June 4, 2025. The presentation will be at 3:00 p.m. Eastern time on Wednesday, June 4, and will be webcast live. Interested parties can register to watch the virtual presentation. Management will also be available for one-on-one meetings with approved investors. Investors interested in attending may visit the event website for more information and to pre-register. Abo
First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, will discuss first quarter 2025 earnings at 5:00 p.m. ET on Thursday, May 8, 2025. Participant details are as follows: U.S. dial-in: 800.579.2543 International dial-in: +1.785.424.1789 Conference ID: PAYSIGN Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13753463 The replay will be available until August 8, 2025. To register as a financial professional in order to ask questions during the call, please email [email protected] no later than 5:00 p.m. ET on Friday, May 2, 2025.
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced its CFO, Jeff Baker, will be attending and presenting at the Ladenburg Thalmann Technology Innovation EXPO25 in New York City on Wednesday, May 21, 2025. Investors interested in attending may visit the event website for more information and to pre-register. About the Ladenburg Thalmann Technology Innovation EXPO25 This full-day conference will showcase approximately 50 cutting-edge technology companies that utilize AI in innovative and breakthrough ways. The format will include three presentat
Live finance-specific insights
Second quarter 2025 total revenues of $19.08 million, up 33.1% from second quarter 2024 Second quarter 2025 net income of $1.39 million, up 99.1% from $697 thousand a year ago, while diluted earnings per share was $0.02, versus $0.01 for second quarter 2024 Second quarter 2025 Adjusted EBITDA of $4.51 million, up 101.8% from $2.24 million a year ago, while diluted Adjusted EBITDA per share was $0.08 versus $0.04 for second quarter 20241 Added 123 net plasma centers during second quarter 2025, all which went live June 16. We exited the quarter with 607 centers; average monthly revenue per plasma center decreased to $7,098 compared to $7,916 for the same period last year; year-over-
First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma
For the Full-Year Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023 Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023 Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per share was $0.17 versus $0.12 for full-year 20231 Total plasma center count increased by 16 during 2024, exiting the year with 480 centers, contributing to a 4.6% increase in plasma revenue versus the same period last year Added 33 net patient affordability programs during 2024, exiting the y
Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde
First quarter 2024 total revenues of $13.2 million, up 30% from first quarter 2023First quarter 2024 net income of $309 thousand, or diluted earnings per share of $0.01, versus net loss of $160 thousand, or diluted earnings per share of $(0.00) for first quarter 2023First quarter 2024 Adjusted EBITDA of $1.7 million, up 135% from $720 thousand for first quarter 2023, while diluted Adjusted EBITDA per share was $0.03 versus $0.01 for first quarter 20231Total plasma center count increased by five net new centers during first quarter 2024, exiting the quarter with 469 centers, contributing to an 11% increase in plasma revenue versus the same period last yearAdded 10 net new patient affordabilit
For the Full YearFull-year 2023 total revenues of $47.3 million, up 24% from full-year 2022Full-year 2023 net income of $6.5 million, or diluted earnings per share of $0.12, versus net income of $1.0 million, or diluted earnings per share of $0.02 for full-year 2022Full-year 2023 Adjusted EBITDA of $6.7 million, up 21% from $5.5 million a year ago, while diluted Adjusted EBITDA per share was $0.12 versus $0.10 for full-year 20221Total plasma center count increased by 20 during 2023, exiting the year with 464 centers, contributing to a 21% increase in plasma revenue versus the same period last yearLaunched 24 net new patient affordability programs during 2023, exiting the year with 43 active
Third quarter total revenues of $12.4 million, an increase of 17% compared to third quarter 2022Third quarter net income of $1.1 million and diluted income per share of $0.02Third quarter Adjusted EBITDA of $2.3 million, an increase of 22% compared to third quarter 2022, and diluted Adjusted EBITDA per share of $0.04, unchanged from third quarter 20221Added 19 net new plasma donation centers during the third quarter, exiting the quarter with 462 centers, leading to a 13% increase in plasma revenue over the same period last yearLaunched three new patient affordability programs during the third quarter, exiting the quarter with 34 active programs, leading to a 142% increase in pharma patient a
Second quarter total revenues of $11.0 million, an increase of 28% compared to second quarter 2022Second quarter net loss of ($0.1) million and diluted loss per share of ($0.00)Second quarter Adjusted EBITDA of $1.1 million, an increase of 23% compared to second quarter 2022, and diluted Adjusted EBITDA per share of $0.02, unchanged from second quarter 2022 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net loss to Adjusted EBITDA at the end of the press release)Added four net new plasma donation centers during the second quarter, exiting the quarter with 443 centersLaunched fiv
First quarter total revenues of $10.1 million, up 23% from first quarter 2022First quarter net loss of ($0.2) million, or diluted loss per share of ($0.00)First quarter Adjusted EBITDA of $0.7 million, down 22% from $0.9 million a year ago, while diluted Adjusted EBITDA per share was $0.01 versus $0.02 for the first quarter 2022 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net loss to Adjusted EBITDA at the end of the press release)Added 10 plasma donation centers during the first quarter, exiting the quarter with 439 centersLaunched seven new patient affordability programs du
Company's Board Authorizes $5 Million Share Repurchase Program For the Full Year Full-year 2022 total revenues of $38.0 million, up 29% from full-year 2021 Full-year 2022 net income of $1.0 million, or diluted earnings per share of $0.02 Full-year 2022 Adjusted EBITDA of $5.5 million, up 175% from $2.0 million a year ago, while diluted Adjusted EBITDA per share was $0.10 versus $0.04 for full-year 2021 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of Net Income to Adjusted EBITDA at the end of the press release) Added 78 net plasma donation centers during 2022, exiting t
This live feed shows all institutional transactions in real time.
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G - Paysign, Inc. (0001496443) (Subject)